ArchiveJanuary 2014

January 2014 natalizumab PML Update

February 2014 natalizumab PML update. #MSBlog #MSResearch “The following are the latest risk figures for PML as a result of being treated with natalizumab. Please note that the embedded slideshow is for health professionals only; I have been told by Biogen-Idec that if you are not a health professional you should not be reading it. if you are a MSer you should be reading my...

Lower Cancer Risk in MS

Catalá-López F, Suárez-Pinilla M, Suárez-Pinilla P, Valderas JM, Gómez-Beneyto M, Martinez S, Balanzá-Martínez V, Climent J, Valencia A, McGrath J, Crespo-Facorro B, Sanchez-Moreno J, Vieta E, Tabarés-Seisdedos R. Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies...

Clinic Speak: pregnancy risks and fingolimod

Did you know highly-effective DMTs increase your chances of falling pregnant? Why? #ClinicSpeak #MSBlog #MSResearch “I have been saying for sometime that we should consider rebranding MS a pink-ribbon disease. MS is a disease of young woman of child-bearing age; female:male ratio is ~3:1 and climbing, mean age of onset is ~30 years of age with the majority of MSers present between the ages...

Hope buffering the Impact of MS

The Stress-Buffering Effects of Hope on Adjustment to Multiple Sclerosis.Madan S, Pakenham KI.Int J Behav Med. 2014 Jan 17. [Epub ahead of print]BACKGROUND:Hope is an important resource for coping with chronic illness; however, the role of hope in adjusting to multiple sclerosis (MS) has been neglected, and the mechanisms by which hope exerts beneficial impacts are not well understood...

Another big beast joins the fray: ofatumumab phase 2 trial results

Another big beast arrives on the MS scene. #MSBlog #MSResearch “MS used to be a orphan disease. Interferon-beta-1a (Avonex) was licensed by the FDA under the orphan drug legislation. What is an orphan disease? Orphan diseases are rare diseases that only affect a small percentage of the population. Orphan drug acts were put in place  to incentivise drug companies to take the...

Cognition problems associated with changes in nerve signalling molecules

Muhlert N, Atzori M, De Vita E, Thomas DL, Samson RS, Wheeler-Kingshott CA, Geurts JJ, Miller DH, Thompson AJ, Ciccarelli O. Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions. J Neurol Neurosurg Psychiatry. 2014 Jan 15 OBJECTIVE: Glutamate is the principal excitatory neurotransmitter and is involved in normal brain function. Cognitive...

Is it morally right to refuse someone a treatment under the NHS because someone else can’t afford it?

The morality of private prescribing in the NHS. #MSBlog #MSResearch “My post yesterday on private prescribing has raised some interesting philosophical questions. An excellent and very though provoking comment today suggest we need to pay more taxes to support the NHS and also questions the morality of a position of principle. Do you agree?” Private prescribing in the NHS –...

Clinic speak: vitamin D levels as a predictor of MS disease activity

Chicken or egg: low vitamin D levels and MS. #MSBlog #MSResearch #ClinicSpeak “Chicken or egg? Vitamin D and MS is another conundrum in need of a solution. We know  that low vD levels are a susceptibility factor for MS and  that MS incidence (number of new cases per year) and prevalence (total number of cases in the population) are strongly associated with latitude (distance from...

Are infections driving T cells to speed progression

Zastepa E, Fitz-Gerald L, Hallett M, Antel J, Bar-Or A, Baranzini S, Lapierre Y, Haegert DG.Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS.Neurology. 2014 Jan. [Epub ahead of print] OBJECTIVE: Our objective was to determine whether altered naive CD4 T-cell biology contributes to development of disease progression in secondary progressive multiple...

Translate

Categories

Recent Posts

Recent Comments

Archives